Navigation Links
OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
Date:10/22/2010

well as for general corporate purposes. 

Stifel Nicolaus Weisel acted as sole book-running manager and Needham & Company, LLC, Rodman & Renshaw, LLC and Wedbush PacGrow Life Sciences acted as co-managers.

The offering was made to purchasers outside of Canada pursuant to an effective shelf registration statement that OncoGenex filed with the Securities and Exchange Commission, or the SEC, on June 26, 2009, as amended on July 13, 2009.  A final prospectus supplement relating to the offering was filed with the SEC on October 19, 2010. Copies of the prospectus supplement and the prospectus relating to these securities may be obtained by contacting Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, Attention: General Counsel, (415) 364-2500.  Electronic copies of the prospectus supplement and accompanying prospectus are also available on the website of the SEC at http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy shares of common stock and warrants of OncoGenex Pharmaceuticals, Inc., nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About OncoGenex
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.  OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirse
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
2. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
3. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
4. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
5. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
6. OncoGenex Reports Second Quarter Financial Results
7. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
9. OncoGenex Reports First Quarter Financial Results
10. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
11. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... (PRWEB) November 20, 2014 Author Matthew ... Walk to the Other Side” published as a ... Finalist in the “Fiction: Short Story” category of the ... Keen, President and CEO of USA Book News, said ... and independent publishers, including Simon & Schuster, Penguin, John ...
(Date:11/21/2014)... November 20, 2014 The November 2014 ... as an open access journal featuring the following articles:, ... proteins to preserve photoresponsiveness in the retina , ... in situ hybridization using chromogenic substrates in zebrafish , ... RNA, and protein electrophoresis , Nuclear LC3-positive ...
(Date:11/21/2014)... Texas (PRWEB) November 21, 2014 ... Sodium Ferrocyanide Industry” is a professional and in-depth ... provides Sodium ferrocyanide information, like its definition, ... as industry overview. This report covers the international ... as global (such as the US, Europe, Asia, ...
(Date:11/21/2014)... 20, 2014 /CNW/ - Aequus Pharmaceuticals Inc. (the ... it has closed a brokered private placement offering ... C$3.7 million.  Cormark Securities Inc. and Clarus Securities ... Offering for a syndicate of agents that also ... (collectively the "Agents"). Concurrently with the Brokered Offering, ...
Breaking Biology Technology:Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3
... ARBOR, Mich.---University of Michigan physicists used the electric fields ... thousands of microscopic plastic spheres, thereby creating 3-D arrays ... be used to analyze the structure of materials of ... physicist Georg Raithel. Raithel is co-author of a ...
... VWR International, LLC, a global leader in ... it acquired the business of BioExpress Corp. ... 1985, BioExpress is a well-respected distributor in the ... over 200 well-known, multi-national brands, including its private ...
... Waters Corporation (NYSE: ... UPLC® I-Class System, the highest performing UPLC® system ... the next level.  For scientists challenged by the ... the lowest system dispersion and lowest carryover in ...
Cached Biology Technology:Lasers used to form 3-D crystals made of nanoparticles 2VWR International, LLC Acquires BioExpress Corp. 2Waters Introduces Highest Performing UPLC Ever Engineered - the New ACQUITY UPLC I-Class 2Waters Introduces Highest Performing UPLC Ever Engineered - the New ACQUITY UPLC I-Class 3Waters Introduces Highest Performing UPLC Ever Engineered - the New ACQUITY UPLC I-Class 4
(Date:11/7/2014)... Nov. 7, 2014  In conjunction with the ... Departments, The Community Foundation of the Verdugos has announced the ... JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo Regional ... its first six months of existence, the Lab has processed ... for local law enforcement. "Because our number one ...
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/4/2014)... right amount of death at the right time might ... new research that could help in understanding animal populations, ... In a paper in the journal Trends in ... European colleagues conclude that the kind of positive population ... individuals, or mortality, depends on the size and developmental ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2When less is more: Death in moderation boosts population density in nature 2
... CORAL GABLES, FL (March 14, 2012)--Convincing speeches are central to ... we select our leaders? A newly-published paper in Proceedings ... men and women vote for male and female candidates with ... found to be perceived as more competent, stronger, and more ...
... DURHAM, N.H. Researchers from the University of ... perceive changes in climate and rainfall when compared with ... to assist them to improve farming practices. "Quantifying ... of which changes matter, is fundamental to addressing the ...
... edge of the University of New Hampshire campus has contributed ... human health. The research, detailed in a recent ... , has found that one type of pavement sealcoat, common ... health and ecosystem implications. Alison Watts, research assistant professor of ...
Cached Biology News:UNH researchers find African farmers need better climate change data to improve farming practices 2UNH research adds to mounting evidence against popular pavement sealcoat 2
Anti-Mouse MIP-1g, Biotin (Polyclonal) (rabbit IgG)...
... E978 GenBank Accession ... Immunogen : NY-ESO-1 full-length ... ascites with 0.05% sodium ... evaluated by immunoblot on ...
... Chicken polyclonal to Opsin 1 ( Abpromise ... Synthetic peptide: YEDSTHASIFTYT, corresponding to amino acids ... synthetic peptide corresponding to amino acids 18/30 of ... used as immunogen. Entrez Gene ...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Biology Products: